Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer

Biomaterials

Volumn 35, Issue 20, 2014, Pages 5347-5358

  Dai, Wenbing ^a   Yang, Fang ^a   Ma, Ling ^a   Fan, Yuchen ^a   He, Bing ^a   He, Qihua ^b   Wang, Xueqing ^a   Zhang, Hua ^b   Zhang, Qiang ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

Combined therapy; Liposomal doxorubicin; Rapamycin; Targeting delivery; Triple negative breast cancer

Indexed keywords

ANTIBIOTICS; DISEASES; LIPOSOMES; TUMORS;

COMBINED THERAPY; LIPOSOMAL DOXORUBICIN; RAPAMYCIN; TARGETING DELIVERIES; TRIPLE-NEGATIVE BREAST CANCERS;

DIAGNOSIS;

ALPHA3 INTEGRIN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; DOXORUBICIN; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; MACROGOL DERIVATIVE; MICELLE; MTOR PROTEIN, HUMAN; POLYMER; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CHEMISTRY; CONFOCAL MICROSCOPY; FEMALE; GENETICS; HUMAN; MCF 7 CELL LINE; METABOLISM; MICELLE; MOUSE; TRANSMISSION ELECTRON MICROSCOPY; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DOXORUBICIN; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTEGRIN ALPHA3; LIPOSOMES; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICELLES; MICROSCOPY, CONFOCAL; MICROSCOPY, ELECTRON, TRANSMISSION; POLYETHYLENE GLYCOLS; POLYMERS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84899471653     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2014.03.036     Document Type: Article

References (49)

1. Shastry M., Yardley D.A. Updates in the treatment of basal/triple-negative breast cancer. Curr Opin Obstet Gynecol 2013, 25:40-48.
2. Podo F., Buydens L.M.C., Degani H., Hilhorst R., Klipp E., Gribbestad I.S., et al. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010, 4:209-229.
3. Hudis C.A., Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist 2011, 16(Suppl. 1):1-11.
4. Griffiths C.L., Olin J.L. Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract 2012, 25:319-323.
5. Gelmon K., Dent R., Mackey J.R., Laing K., McLeod D., Verma S. Targeting triple-negative breast cancer: optimising therapeutic outcomes. Ann Oncol 2012, 23:2223-2234.
6. Criscitiello C., Azim H.A., Schouten P.C., Linn S.C., Sotiriou C. Understanding the biology of triple-negative breast cancer. Ann Oncol 2012, 23(Suppl. 6):vi13-vi18.
7. Crown J., O'Shaughnessy J., Gullo G. Emerging targeted therapies in triple-negative breast cancer. Ann Oncol 2012, 23(Suppl. 6):vi56-vi65.
8. Turner N., Moretti E., Siclari O., Migliaccio I., Santarpia L., D'Incalci M., et al. Targeting triple negative breast cancer: Is p53 the answer?. Cancer Treat Rev 2013, 39:541-550.
9. Bayraktar S., Glück S. Molecularly targeted therapies for metastatic triple-negative breast cancer. Breast Cancer Res Treat 2013, 138:21-35.
10. Perren A., Weng L.P., Boag A.H., Ziebold U., Thakore K., Dahia P.L., et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 1999, 155:1253-1260.
11. Saal L.H., Holm K., Maurer M., Memeo L., Su T., Wang X., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005, 65:2554-2559.
12. Yunokawa M., Koizumi F., Kitamura Y., Katanasaka, Okamoto N., Yonemori K., et al. Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 2012, 103(9):1665-1671.
13. Noh W.C., Mondesier W.H., Peng J., Jian W., Zhang H., Dong J., et al. Determinants of rapamycin sensitivity in breast cancer cells. Clin Cancer Res 2004, 10(3):1013-1023.
14. Ueng S.H., Chen S.C., Chang Y.S., Hsueh S., Lin Y.C., Chien H.P., et al. Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas. Int J Clin Exp Pathol 2012, 5:806-813.
15. Walsh S., Flanagan L., Quinn C., Evoy D., McDermott E.W., Pierce A., et al. mTOR in breast cancer: differential expression in triple-negative and non-triple-negative tumors. Breast 2012, 21:178-182.
16. Yellen P., Saqcena M., Salloum D., Feng J., Preda A., Xu L., et al. High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 2011, 10:3948-3956.
17. Loehberg C.R., Strissel P.L., Dittrich R., Strick R., Dittmer J., Fabry B., et al. Akt and p53 are potential mediators of reduced mammary tumor growth by chloroquine and the mTOR inhibitor RAD001. Biochem Pharmacol 2012, 83:480-488.
18. Chen Y., Zheng Y., Foster D.A. Phospholipase D confers rapamycin resistance in human breast cancer cells. Oncogene 2003, 22:3937-3942.
19. He X., Wang Y., Zhu J., Orloff M., Eng C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett 2011, 301:168-176.
20. Zeng Q., Yang Z., Gao Y.J., Yuan H., Cui K., Shi Y., et al. Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 2010, 46:1132-1143.
21. Duyndam M.C., van Berkel M.P., Dorsman J.C., Rockx D.A., Pinedo H.M., Boven E. Cisplatin and doxorubicin repress vascular endothelial growth factor expression and differentially down-regulate hypoxia-inducible factor I activity in human ovarian cancer cells. Biochem Pharmacol 2007, 74:191-201.
22. Liu H., Zang C., Schefe J.H., Schwarzlose-Schwarck S., Regierer A.C., Elstner E., et al. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro. Anticancer Res 2011, 31:2713-2722.
23. Romano M.F., Avellino R., Petrella A., Bisogni R., Romano S., Venuta S. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004, 40:2829-2836.
24. Fang Y., Sullivan R., Graham C.H. Confluence-dependent resistance to doxorubicin in human MDA-MB-231 breast carcinoma cells requires hypoxia-inducible factor-1 activity. Exp Cell Res 2007, 313:867-877.
25. Sishi B.J., Loos B., van Rooyen J., Engelbrecht A.M. Autophagy upregulation promotes survival and attenuates doxorubicin-induced cardiotoxicity. Biochem Pharmacol 2012, 85:124-134.
26. Cao Y., Eble J.M., Moon E., Yuan H., Weitzel D.H., Landon C.D., et al. Tumor cells upregulate normoxic HIF-1alpha in response to doxorubicin. Cancer Res 2013, 73:6230-6242.
27. Land S.C., Tee A.R. Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif. J Biol Chem 2007, 282:20534-20543.
28. Wang W., Jia W.D., Xu G.L., Wang Z.H., Li J.S., Ma J.L., et al. Antitumoral activity of rapamycin mediated through inhibition of HIF-1alpha and VEGF in hepatocellular carcinoma. Dig Dis Sci 2009, 54:2128-2136.
29. Moroney J.W., Schlumbrecht M.P., Helgason T., Coleman R.L., Moulder S., Naing A., et al. A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 2011, 17:6840-6846.
30. Yao N., Xiao W., Wang X., Marik J., Park S.H., Takada Y., et al. Discovery of targeting ligands for breast cancer cells using the one-bead one-compound combinatorial method. J Med Chem 2009, 52:126-133.
31. Yao N., Xiao W., Meza L., Tseng H., Chuck M., Lam K.S. Structure-activity relationship studies of targeting ligands against breast cancer cells. J Med Chem 2009, 52:6744-6751.
32. 2)-Gly-ProOH-Asn-D-Cys-biotin-streptavidin-Cy5.5. Molecular imaging and contrast agent database (MICAD) [Internet] 2013, National Center for Biotechnology Information (US), Bethesda (MD).
33. Niu G., Chen X. Why integrin as a primary target for imaging and therapy. Theranostics 2011, 1:30-47.
34. Xiang Y., Liang L., Wang X., Wang J., Zhang X., Zhang Q. Chloride channel-mediated brain glioma targeting of chlorotoxin-modified doxorubicine-loaded liposomes. J Control Release 2011, 152:402-410.
35. Chen Y.C., Lo C.L., Lin Y.F., Hsiue G.H. Rapamycin encapsulated in dual-responsive micelles for cancer therapy. Biomaterials 2013, 34:1115-1127.
36. Fan Y., Du W., He B., Fu F., Yuan L., Wu H., et al. The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin. Biomaterials 2013, 34:2277-2288.
37. Haran G., Cohen R., Bar L.K., Barenholz Y. Transmembrane ammonium sulfate gradient in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta 1993, 1151:201-215.
38. Vichai V., Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006, 1:1112-1116.
39. Bisht S., Feldmann G., Koorstra J.B., Mullendore M., Alvarez H., Karikari C., et al. In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities. Mol Cancer Ther 2008, 7:3878-3888.
40. Zheng N., Dai W., Du W., Zhang H., Lei L., Zhang H., et al. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors. Mol Pharmacol 2012, 9:1175-1188.
41. Lundstrom A., Holmbom J., Lindqvist C., Nordstrom T. The role of α2β1 and α3β1 integrin receptors in the initial anchoring of MDA-MB-231 human breast cancer cells to cortical bone matrix. Biochem Biophys Res Commun 1998, 250:735-740.
42. Monica M., Marcella M., Ferrari N., Ghiorzo F., Buglioni S., Mortarini R., et al. The α3β1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. Int J Cancer 2000, 87:336-342.
43. Düzgüneş N., Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliv Rev 1999, 40:3-18.
44. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006, 58:621-681.
45. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
46. Sharma P., Brown S., Walter G., Santra S., Moudgil B. Nanoparticles for bioimaging. Adv Colloid Interface Sci 2006, 123-126:471-485.
47. Schädlich A., Rose C., Kuntsche J., Caysa H., Mueller T., Göpferich A. How stealthy are PEG-PLA nanoparticles? An NIR in vivo study combined with detailed size measurements. Pharm Res 2011, 28:1995-2007.
48. Kwon I.K., Lee S.C., Han B., Park K. Analysis on the current status of targeted drug delivery to tumors. J Control Release 2012, 164:108-114.
49. Shi Y., Chang M., Wang F., Ouyang X., Jia Y., Du H. Role and mechanism of hypoxia-inducible factor-1 in cell growth and apoptosis of breast cancer cell line MDA-MB-231. Oncol Lett 2010, 1:657-662.